Cannabis MS benefits 'subjective'
Long-awaited results from the first large-scale randomised
trial of the use of cannabinoids in multiple sclerosis present a mixed picture.
The researchers, who were funded by the Medical Research Council, found no improvement in spasticity compared with a placebo using objective measures, according to results printed in The Lancet (November 8).
But 60 per cent of patients in the cannabinoid groups reported subjective improvements in spasticity compared to 37 per cent in the placebo group.
The researchers said patients' awareness of which treatment they were receiving, owing to side-effects, could explain this as cannabis had been linked anecdotally to improvements in MS symptoms.
The research team concluded that cannabinoids may have potential clinical use in improving mobility and pain control in MS.